Pomalidomide for Kaposi Sarcoma in People With or Without HIV
NCT ID: NCT01495598
Last Updated: 2022-11-01
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
28 participants
Study Classification
INTERVENTIONAL
Study Start Date
2012-01-10
Study Completion Date
2022-05-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
\- Pomalidomide is a drug that can treat cancer through several mechanisms. It is taken by mouth (orally). Pomalidomide can help treat cancer by blocking certain factors that promote tumor growth or by stimulating the immune system to attack tumor cells. It also prevents the growth of new blood vessels that help cancer grow. Researchers want to see if pomalidomide can treat Kaposi sarcoma, a rare and potentially fatal skin cancer. Because Kaposi sarcoma may be associated with human immunodeficiency virus (HIV) infection, researchers want to test the drug in people with and without HIV infection.
Objectives:
\- To see if pomalidomide is a safe and effective treatment for Kaposi sarcoma in people with or without HIV.
Eligibility:
* Individuals at least 18 years of age who have Kaposi sarcoma.
* Participants may or may not have HIV infection.
Design:
* Potential participants will be screened with a medical history and physical exam. Blood and saliva samples will be taken and a chest X-ray will be performed. A skin biopsy of a Kaposi sarcoma lesion may be performed if one has not already been done. Other imaging studies may be performed if needed.
* Participants will take pomalidomide capsules every day for 3 weeks, followed by a 1-week break. These 28 days are one cycle of treatment.
* Participants will have up six cycles of treatment, unless the lesions completely resolve sooner. If there are signs of improvement after six cycles but the lesions are not completely gone, up to another six cycles of treatment may be given.
* Treatment will be monitored with frequent blood tests and other studies including photograph and other imaging of skin lesions.
* Participants will have regular follow-up visits for 5 years after stopping treatment....
\- Pomalidomide is a drug that can treat cancer through several mechanisms. It is taken by mouth (orally). Pomalidomide can help treat cancer by blocking certain factors that promote tumor growth or by stimulating the immune system to attack tumor cells. It also prevents the growth of new blood vessels that help cancer grow. Researchers want to see if pomalidomide can treat Kaposi sarcoma, a rare and potentially fatal skin cancer. Because Kaposi sarcoma may be associated with human immunodeficiency virus (HIV) infection, researchers want to test the drug in people with and without HIV infection.
Objectives:
\- To see if pomalidomide is a safe and effective treatment for Kaposi sarcoma in people with or without HIV.
Eligibility:
* Individuals at least 18 years of age who have Kaposi sarcoma.
* Participants may or may not have HIV infection.
Design:
* Potential participants will be screened with a medical history and physical exam. Blood and saliva samples will be taken and a chest X-ray will be performed. A skin biopsy of a Kaposi sarcoma lesion may be performed if one has not already been done. Other imaging studies may be performed if needed.
* Participants will take pomalidomide capsules every day for 3 weeks, followed by a 1-week break. These 28 days are one cycle of treatment.
* Participants will have up six cycles of treatment, unless the lesions completely resolve sooner. If there are signs of improvement after six cycles but the lesions are not completely gone, up to another six cycles of treatment may be given.
* Treatment will be monitored with frequent blood tests and other studies including photograph and other imaging of skin lesions.
* Participants will have regular follow-up visits for 5 years after stopping treatment....
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
NCT02659930
Kaposi Sarcoma
ACTIVE_NOT_RECRUITING
PHASE1
Pomalidomide Treatment in Patients With Kaposi Sarcoma
NCT04577755
Skin Kaposi Sarcoma
ACTIVE_NOT_RECRUITING
PHASE2
Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
NCT03601806
Human Immunodeficiency Virus 1 Positive
Skin Kaposi Sarcoma
COMPLETED
PHASE2
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
NCT04941274
Kaposi Sarcoma
RECRUITING
PHASE1/PHASE2
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
NCT03157167
Kaposi Sarcoma
HIV Infections
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Kaposi Sarcoma (KS) is an incurable, multicentric angioproliferative tumor that most frequently involves the skin. It is seen most frequently in people with human immunodeficiency virus (HIV) or other forms of immune compromise. Current therapies are limited by toxicities, including cumulative cardiotoxicity, while effective oral agents, agents deliverable in resource-limited settings, and agents deliverable long-term for relapsing disease are all lacking.
Objective:
The primary objective of this study is to:
Assess the safety, tolerability and pharmacokinetics of pomalidomide in subjects with Kaposi sarcoma, whether HIV associated or not.
Eligibility:
* Age greater than or equal to 18 years
* Measurable, pathologically confirmed KS
* Any HIV status; HIV-associated KS subjects must be receiving and able to comply with highly active antiretroviral therapy (HAART) and have achieved an HIV viral load \<10,000 copies/mL
* Hematologic and biochemical parameters within prespecified limits at baseline
* Willing to use effective birth control, as defined in the full protocol
* For subjects enrolled in the anti-tumor activity assessment phase, if KS is HIV-associated it must be increasing despite HAART and HIV suppression for greater than or equal to 2 months, or stable despite HAART for greater than or equal to 3 months
* No symptomatic pulmonary or visceral KS
* No specific KS therapy within 4 weeks (6 weeks if that therapy was bevacizumab)
* Neither pregnant nor breast feeding
Design:
This is an open label single agent phase I/II study of pomalidomide in patients with KS. In the phase I portion, up to six subjects will initially be treated with pomalidomide 5mg daily for 21 days of a 28 day cycle. Subject to toxicity evaluation, this dosage may be deescalated to 3mg daily for 21 days of a 28 day cycle in a second cohort of up to six subjects. If either dose proves tolerable, the study will proceed to the phase II portion, and additional subjects to a goal of 15 HIV positive and 10 HIV negative subjects evaluable for response will be added at the highest tolerable dose to gain preliminary information on activity.
Kaposi Sarcoma (KS) is an incurable, multicentric angioproliferative tumor that most frequently involves the skin. It is seen most frequently in people with human immunodeficiency virus (HIV) or other forms of immune compromise. Current therapies are limited by toxicities, including cumulative cardiotoxicity, while effective oral agents, agents deliverable in resource-limited settings, and agents deliverable long-term for relapsing disease are all lacking.
Objective:
The primary objective of this study is to:
Assess the safety, tolerability and pharmacokinetics of pomalidomide in subjects with Kaposi sarcoma, whether HIV associated or not.
Eligibility:
* Age greater than or equal to 18 years
* Measurable, pathologically confirmed KS
* Any HIV status; HIV-associated KS subjects must be receiving and able to comply with highly active antiretroviral therapy (HAART) and have achieved an HIV viral load \<10,000 copies/mL
* Hematologic and biochemical parameters within prespecified limits at baseline
* Willing to use effective birth control, as defined in the full protocol
* For subjects enrolled in the anti-tumor activity assessment phase, if KS is HIV-associated it must be increasing despite HAART and HIV suppression for greater than or equal to 2 months, or stable despite HAART for greater than or equal to 3 months
* No symptomatic pulmonary or visceral KS
* No specific KS therapy within 4 weeks (6 weeks if that therapy was bevacizumab)
* Neither pregnant nor breast feeding
Design:
This is an open label single agent phase I/II study of pomalidomide in patients with KS. In the phase I portion, up to six subjects will initially be treated with pomalidomide 5mg daily for 21 days of a 28 day cycle. Subject to toxicity evaluation, this dosage may be deescalated to 3mg daily for 21 days of a 28 day cycle in a second cohort of up to six subjects. If either dose proves tolerable, the study will proceed to the phase II portion, and additional subjects to a goal of 15 HIV positive and 10 HIV negative subjects evaluable for response will be added at the highest tolerable dose to gain preliminary information on activity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Kaposi Sarcoma
Sarcoma, Kaposi
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1 Pomalidomide 5mg Daily
Up to six subjects will initially be treated with for 21 days of a 28 day cycle
Group Type
EXPERIMENTAL
Pomalidomide
Intervention Type
DRUG
5 mg by mouth (p.o.) for 21 of 28 days
Phase 2 Pomalidomide 5mg Daily
15 human immunodeficiency virus (HIV) positive and 10 HIV negative subjects evaluable for response will be treated with Pomalidomide 5mg daily for 21 days of a 28 day cycle
Group Type
EXPERIMENTAL
Pomalidomide
Intervention Type
DRUG
5 mg by mouth (p.o.) for 21 of 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pomalidomide
5 mg by mouth (p.o.) for 21 of 28 days
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
POMALYST®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age greater than or equal to 18 Years.
* Any human immunodeficiency virus (HIV) status.
* Kaposi sarcoma pathologically confirmed by Department of Pathology, Clinical Center, National Institutes of Health.
* At least five measurable Kaposi sarcoma (KS) lesions with no previous local radiation, surgical or intralesional cytotoxic therapy that would prevent response assessment for that lesion.
* Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2
* Life expectancy greater than or equal to 6 months
* For patients with HIV-associated KS:
* Must be receiving, and adherent to, a highly active antiretroviral therapy (HAART) regimen consistent with current clinical guidelines.
* Must have been receiving HAART for at least one month.
* Must have achieved an HIV viral load (VL) \<10,000 copies/mL.
* The following hematological parameters:
* Hemoglobin greater than or equal to 10 g/dL
* Platelets greater than or equal to 75,000 cells/mm(3)
* Absolute neutrophil count (ANC) greater than or equal to 1000 cells/mm(3)
* The following biochemical parameters:
* Estimated or measured creatinine clearance greater than or equal to 45mL/minute
* Serum alanine aminotransferase (ALT) less than or equal to 2.5 times upper limit of normal
* Serum aspartate aminotransferase (AST) less than or equal to 2.5 times upper limit of normal
* Bilirubin less than or equal to 1.5 times upper limit of normal unless the patient is receiving protease inhibitor therapy (e.g., indinavir, ritonavir, nelfinavir, or atazanavir) known to be associated with increased bilirubin, in which case total bilirubin less than or equal to 7.5 mg/dL with direct fraction less than or equal to 0.7 mg/dL.
* Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to and again within 24 hours before starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, and also
* All study participants must agree to be registered into the mandatory POMALYST Risk Evaluation and Mitigation Strategy (REMS) program and be willing and able to comply with the requirements of the POMALYST REMS program.
* Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS program.
* Able to take aspirin 81mg daily or if intolerant of aspirin, able to take a substitute thromboprophylaxis such as low molecular weight heparin at a thromboprophylactic dose (such as enoxaparin 0.5mg/kg once daily).
* Willing and able to give informed consent.
* For subjects with HIV-associated entered after a tolerable dose has been determined, KS lesions must be either:
* Increasing despite HAART and HIV suppression below the limit of detection (48 copies/mL) in the two months prior to screening or
* Stable despite HAART for at least three months. Stable disease must be symptomatic (examples of symptomatic disease include disease associated with pain, edema, psychological distress and/or social withdrawal). This is to gain preliminary information about pomalidomide activity without confounding due to HAART initiation.
* Any human immunodeficiency virus (HIV) status.
* Kaposi sarcoma pathologically confirmed by Department of Pathology, Clinical Center, National Institutes of Health.
* At least five measurable Kaposi sarcoma (KS) lesions with no previous local radiation, surgical or intralesional cytotoxic therapy that would prevent response assessment for that lesion.
* Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2
* Life expectancy greater than or equal to 6 months
* For patients with HIV-associated KS:
* Must be receiving, and adherent to, a highly active antiretroviral therapy (HAART) regimen consistent with current clinical guidelines.
* Must have been receiving HAART for at least one month.
* Must have achieved an HIV viral load (VL) \<10,000 copies/mL.
* The following hematological parameters:
* Hemoglobin greater than or equal to 10 g/dL
* Platelets greater than or equal to 75,000 cells/mm(3)
* Absolute neutrophil count (ANC) greater than or equal to 1000 cells/mm(3)
* The following biochemical parameters:
* Estimated or measured creatinine clearance greater than or equal to 45mL/minute
* Serum alanine aminotransferase (ALT) less than or equal to 2.5 times upper limit of normal
* Serum aspartate aminotransferase (AST) less than or equal to 2.5 times upper limit of normal
* Bilirubin less than or equal to 1.5 times upper limit of normal unless the patient is receiving protease inhibitor therapy (e.g., indinavir, ritonavir, nelfinavir, or atazanavir) known to be associated with increased bilirubin, in which case total bilirubin less than or equal to 7.5 mg/dL with direct fraction less than or equal to 0.7 mg/dL.
* Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to and again within 24 hours before starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods, and also
* All study participants must agree to be registered into the mandatory POMALYST Risk Evaluation and Mitigation Strategy (REMS) program and be willing and able to comply with the requirements of the POMALYST REMS program.
* Females of reproductive potential must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS program.
* Able to take aspirin 81mg daily or if intolerant of aspirin, able to take a substitute thromboprophylaxis such as low molecular weight heparin at a thromboprophylactic dose (such as enoxaparin 0.5mg/kg once daily).
* Willing and able to give informed consent.
* For subjects with HIV-associated entered after a tolerable dose has been determined, KS lesions must be either:
* Increasing despite HAART and HIV suppression below the limit of detection (48 copies/mL) in the two months prior to screening or
* Stable despite HAART for at least three months. Stable disease must be symptomatic (examples of symptomatic disease include disease associated with pain, edema, psychological distress and/or social withdrawal). This is to gain preliminary information about pomalidomide activity without confounding due to HAART initiation.
Exclusion Criteria
* Symptomatic pulmonary KS.
* Symptomatic visceral KS (except for non-ulcerating disease restricted to the oral cavity).
* Specific KS therapy, including cytotoxic chemotherapy but not including HAART, within the past 4 weeks (6 weeks if the therapy was bevacizumab).
* Use of other anticancer treatments or agents within the past 4 weeks (6 weeks if the therapy was a monoclonal antibody).
* History of malignant tumors other than KS, unless:
* In complete remission for greater than or equal to 1 year from the time response was first documented or
* Completely resected basal cell carcinoma or
* In situ squamous cell carcinoma of the cervix or anus.
* History of infection meeting any of the following criteria:
* Any infection that would be scored as grade 4 by Common Terminology Criteria for Adverse Events (CTCAE) that occurred within six weeks of study screening.
* Any infection that would be scored as grade 3 by CTCAE that occurred within two weeks of study screening.
* History of fungal and mycobacterial infections, unless at least six weeks has passed since the completion of induction antimicrobial therapy. Patients may be receiving consolidation therapy for infections of these types.
* Any abnormality that would be scored as a greater than or equal to grade 3 toxicity by CTCAE, except:
* Obesity is not considered an abnormality for the purposes of eligibility assessment unless in the opinion of the Principal Investigator or Lead Associate Investigator its clinical consequences in a particular subject places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.
* Lymphopenia
* Asymptomatic hyperuricemia, hypophosphatemia, or creatine kinase (CK) Elevations
* Direct manifestations of KS
* Direct manifestations of HIV infection, except for neurologic or cardiac manifestations
* Direct manifestations of HIV therapy, except for neurologic or cardiac manifestations.
* History of venous or arterial thromboembolism, unless:
* Line-related thrombosis without embolus occurring greater than or equal to 1 year prior to screening.
* Known drug-related, inherited, or acquired procoagulant disorder including prothrombin gene mutation 20210, antithrombin III deficiency, protein C deficiency, protein S deficiency and antiphospholipid syndrome but not including heterozygosity for the Factor V Leiden mutation or the presence of a lupus anticoagulant in the absence of other criteria for the antiphospholipid syndrome.
* Pregnancy.
* Breast feeding (if lactating, must agree not to breast feed while taking pomalidomide).
* Prior therapy with pomalidomide.
* Known hypersensitivity to thalidomide, lenalidomide or pomalidomide. including prior development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or pomalidomide.
* Any condition, including the presence of laboratory abnormalities, which in the opinion of the Principal Investigator or Lead Associate Investigator places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.
* Symptomatic visceral KS (except for non-ulcerating disease restricted to the oral cavity).
* Specific KS therapy, including cytotoxic chemotherapy but not including HAART, within the past 4 weeks (6 weeks if the therapy was bevacizumab).
* Use of other anticancer treatments or agents within the past 4 weeks (6 weeks if the therapy was a monoclonal antibody).
* History of malignant tumors other than KS, unless:
* In complete remission for greater than or equal to 1 year from the time response was first documented or
* Completely resected basal cell carcinoma or
* In situ squamous cell carcinoma of the cervix or anus.
* History of infection meeting any of the following criteria:
* Any infection that would be scored as grade 4 by Common Terminology Criteria for Adverse Events (CTCAE) that occurred within six weeks of study screening.
* Any infection that would be scored as grade 3 by CTCAE that occurred within two weeks of study screening.
* History of fungal and mycobacterial infections, unless at least six weeks has passed since the completion of induction antimicrobial therapy. Patients may be receiving consolidation therapy for infections of these types.
* Any abnormality that would be scored as a greater than or equal to grade 3 toxicity by CTCAE, except:
* Obesity is not considered an abnormality for the purposes of eligibility assessment unless in the opinion of the Principal Investigator or Lead Associate Investigator its clinical consequences in a particular subject places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.
* Lymphopenia
* Asymptomatic hyperuricemia, hypophosphatemia, or creatine kinase (CK) Elevations
* Direct manifestations of KS
* Direct manifestations of HIV infection, except for neurologic or cardiac manifestations
* Direct manifestations of HIV therapy, except for neurologic or cardiac manifestations.
* History of venous or arterial thromboembolism, unless:
* Line-related thrombosis without embolus occurring greater than or equal to 1 year prior to screening.
* Known drug-related, inherited, or acquired procoagulant disorder including prothrombin gene mutation 20210, antithrombin III deficiency, protein C deficiency, protein S deficiency and antiphospholipid syndrome but not including heterozygosity for the Factor V Leiden mutation or the presence of a lupus anticoagulant in the absence of other criteria for the antiphospholipid syndrome.
* Pregnancy.
* Breast feeding (if lactating, must agree not to breast feed while taking pomalidomide).
* Prior therapy with pomalidomide.
* Known hypersensitivity to thalidomide, lenalidomide or pomalidomide. including prior development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or pomalidomide.
* Any condition, including the presence of laboratory abnormalities, which in the opinion of the Principal Investigator or Lead Associate Investigator places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert Yarchoan
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Yarchoan, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Krown SE. AIDS-associated Kaposi's sarcoma: pathogenesis, clinical course and treatment. AIDS. 1988 Apr;2(2):71-80. No abstract available.
Reference Type
BACKGROUND
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994 Dec 16;266(5192):1865-9. doi: 10.1126/science.7997879.
Reference Type
BACKGROUND
Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. Cancer Lett. 2011 Jun 28;305(2):150-62. doi: 10.1016/j.canlet.2011.02.006. Epub 2011 Mar 4.
Reference Type
BACKGROUND
Feinberg J, Saag M, Squires K, Currier J, Ryan R, Coate B, Mrus J. Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat. 2011;2011:349165. doi: 10.1155/2011/349165. Epub 2011 Aug 28.
Reference Type
BACKGROUND
Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010 Aug 15;116(16):3969-77. doi: 10.1002/cncr.25362.
Reference Type
BACKGROUND
Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010 Aug 1;51(3):350-8. doi: 10.1086/654798.
Reference Type
BACKGROUND
Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, Maldarelli F, Whitby D, Marshall V, Goncalves PH, Khetani V, Figg WD, Steinberg SM, Zeldis JB, Yarchoan R. Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. J Clin Oncol. 2016 Dec;34(34):4125-4131. doi: 10.1200/JCO.2016.69.3812. Epub 2016 Oct 31.
Reference Type
RESULT
Ramaswami R, Polizzotto MN, Lurain K, Wyvill KM, Widell A, George J, Goncalves P, Steinberg SM, Whitby D, Uldrick TS, Yarchoan R. Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clin Cancer Res. 2022 Mar 1;28(5):840-850. doi: 10.1158/1078-0432.CCR-21-3364.
Reference Type
RESULT
Lurain K, Polizzotto MN, Krug LT, Shoemaker G, Singh A, Jensen SMR, Wyvill KM, Ramaswami R, Uldrick TS, Yarchoan R, Sereti I. Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration. AIDS. 2023 Sep 1;37(11):1693-1703. doi: 10.1097/QAD.0000000000003627. Epub 2023 Jun 19.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2012-C-0047.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-C-0047
Identifier Type: -
Identifier Source: secondary_id
120047
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
NCT00002147
COMPLETED
PHASE3
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
NCT01016730
COMPLETED
PHASE1
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00427414
TERMINATED
PHASE1
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
NCT01057121
COMPLETED
PHASE1/PHASE2
Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00450320
COMPLETED
PHASE1
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
NCT00717522
TERMINATED
PHASE2
Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma
NCT00003419
UNKNOWN
PHASE2
CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
NCT00017446
UNKNOWN
PHASE2
A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma
NCT00000954
COMPLETED
PHASE1
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
NCT04200443
ACTIVE_NOT_RECRUITING
PHASE2
Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma
NCT00019123
COMPLETED
PHASE2
Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma
NCT00002985
COMPLETED
PHASE3
Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy
NCT00000807
COMPLETED
PHASE2
A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
NCT00000996
COMPLETED
PHASE2
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
NCT00005042
COMPLETED
PHASE2
Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma
NCT00295984
COMPLETED
PHASE2
Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma
NCT00002259
COMPLETED
PHASE2
A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma
NCT00000763
COMPLETED
PHASE1
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
NCT00003718
UNKNOWN
PHASE2
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
NCT00000987
COMPLETED
PHASE1
Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma
NCT01067690
COMPLETED
PHASE2
Thalidomide in Treating Patients With Gynecologic Sarcomas
NCT00006005
COMPLETED
PHASE2
Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir
NCT00362310
COMPLETED
PHASE2
A Study of Selumetinib in Patients With Kaposi's Sarcoma
NCT01752569
TERMINATED
PHASE1/PHASE2
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
NCT04893018
TERMINATED
PHASE1